SCHEMBL23659151

SCHEMBL23659151

NCCN(CCN)C(=O)OCCOCCO

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
TSHR P16473 3/20 0.37
MAPK1 P28482 1/20 0.37
ALDH1A1 P00352 2/20 0.31
TP53 P04637 2/20 0.31
HIF1A Q16665 2/20 0.31
HSD17B10 Q99714 2/20 0.31
CHRNB2 P17787 2/20 0.31
CHRNA4 P43681 2/20 0.31
BLM P54132 1/20 0.31
PMP22 Q01453 1/20 0.31
CHRM2 P08172 1/20 0.31
CHRM4 P08173 1/20 0.31
CHRM5 P08912 1/20 0.31
CHRM1 P11229 1/20 0.31
CHRM3 P20309 1/20 0.31
THRB P10828 1/20 0.31
HTT P42858 1/20 0.31
MAPT P10636 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24092261 0.92 MEN1 (0.37) MEN1KMT2ATSHRMAPK1ALDH1A1
SCHEMBL14005175 0.82 CHRNB2 (0.38) MEN1KMT2ATSHRMAPK1ALDH1A1
SCHEMBL22098728 0.81 MEN1 (0.42) MEN1KMT2ATSHRMAPK1ALDH1A1
SCHEMBL13448559 0.76 CHRNB2 (0.37) CHRNB2CHRNA4CHRM2CHRM4CHRM5
SCHEMBL10619053 0.76 MEN1 (0.46) MEN1KMT2ATSHRMAPK1ALDH1A1
SCHEMBL1416144 0.76 TSHR (0.39) MEN1KMT2ATSHRMAPK1HSD17B10
SCHEMBL14433146 0.75 CHRNB2 (0.41) TSHRCHRNB2CHRNA4CHRM2CHRM4
SCHEMBL22239380 0.75 CA14 (0.41) MEN1KMT2ATSHRMAPK1
SCHEMBL2822780 0.73 CHRNB2 (0.40) TSHRMAPK1CHRNB2CHRNA4CHRM2
SCHEMBL14005100 0.72 CA12 (0.41) TSHRMAPK1ALDH1A1TP53HIF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230190951-A1 CONJUGATES OF ANTIBODIES AN IMMUNE CELL ENGAGERS SYNAFFIX B.V. (NL) 2023-06-22 US disclosed
US-20230114866-A1 VIA CYCLOADDITION BILATERALLY FUNCTIONALIZED ANTIBODIES SYNAFFIX B.V. (NL) 2023-04-13 US disclosed
WO-2021144314-A1 VIA CYCLOADDITION BILATERALLY FUNCTIONALIZED ANTIBODIES SYNAFFIX B.V. (NL) 2021-07-22 WO disclosed
WO-2021144313-A1 VIA CYCLOADDITION BILATERALLY FUNCTIONALIZED ANTIBODIES SYNAFFIX B.V. (NL) 2021-07-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230114866-A1 VIA CYCLOADDITION BILATERALLY FUNCTIONALIZED ANTIBODIES FUT5, FUCA1, FUT6 MEN1 568/4885KMT2A 2418/4885TSHR 1151/4885
US-20230190951-A1 CONJUGATES OF ANTIBODIES AN IMMUNE CELL ENGAGERS FCGR3B, FCGR1A, FCGR2A MEN1 2045/4885KMT2A 760/4885TSHR 780/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.